Connect your AI

KRAKacquisition KRAQ Issuance of warrants to purchase common stock

Issuance of warrants to purchase common stock at other companies

Oruka Therapeutics, Inc.ORKA

$2.52M-75.7%

ADMA BiologicsADMA

$1.4M—

Evommune EVMN

$150—

NovaGold ResourcesNG

$9.9M—

GigaCloud TechnologyGCT

$187K0.0%

Taysha Gene Therapies, Inc.TSHA

$409.25K—

Other financials

Income statement

Operating income-$11.0M—

Net income-$8.9M—

EPS (diluted)-$0.01—

Balance sheet

Cash & equivalents$824.6K—

Total debt$77.4K—

Total equity-$19.9M—

Total assets$348.0M—

Cash flow

Operating cash flow-$669.9K—

Valuation

Market cap$430.77M+0.9%

Enterprise value$430.02M—

Returns & leverage

Debt / equity-0×—

Current ratio7.7×—

Where this comes from

Reported directly by KRAKacquisition in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.

The official record: KRAKacquisition ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about KRAKacquisition 's issuance of warrants to purchase common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is KRAKacquisition 's issuance of warrants to purchase common stock?: KRAKacquisition (KRAQ) reported issuance of warrants to purchase common stock of $2.25M in Q1 2026.